AU742748B2 - Method of preparing a poorly crystalline calcium phosphate and methods of its use - Google Patents
Method of preparing a poorly crystalline calcium phosphate and methods of its use Download PDFInfo
- Publication number
- AU742748B2 AU742748B2 AU46746/97A AU4674697A AU742748B2 AU 742748 B2 AU742748 B2 AU 742748B2 AU 46746/97 A AU46746/97 A AU 46746/97A AU 4674697 A AU4674697 A AU 4674697A AU 742748 B2 AU742748 B2 AU 742748B2
- Authority
- AU
- Australia
- Prior art keywords
- calcium phosphate
- bone
- pca
- phosphate
- calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 title claims abstract description 491
- 239000001506 calcium phosphate Substances 0.000 title claims abstract description 483
- 235000011010 calcium phosphates Nutrition 0.000 title claims abstract description 476
- 229910000389 calcium phosphate Inorganic materials 0.000 title claims abstract description 449
- 238000000034 method Methods 0.000 title claims abstract description 123
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 312
- 239000000463 material Substances 0.000 claims abstract description 293
- 239000007943 implant Substances 0.000 claims abstract description 167
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 90
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims abstract description 65
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims abstract description 64
- 230000007547 defect Effects 0.000 claims abstract description 53
- 230000000153 supplemental effect Effects 0.000 claims abstract description 24
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 claims description 179
- 239000000203 mixture Substances 0.000 claims description 111
- 239000011575 calcium Substances 0.000 claims description 76
- 239000003462 bioceramic Substances 0.000 claims description 39
- 229910052791 calcium Inorganic materials 0.000 claims description 30
- 235000001465 calcium Nutrition 0.000 claims description 30
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 29
- -1 heptacalcium decaphosphate Chemical compound 0.000 claims description 29
- 239000002245 particle Substances 0.000 claims description 28
- 239000007788 liquid Substances 0.000 claims description 23
- 229910019142 PO4 Inorganic materials 0.000 claims description 21
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 21
- 238000002156 mixing Methods 0.000 claims description 19
- 235000021317 phosphate Nutrition 0.000 claims description 19
- 239000012530 fluid Substances 0.000 claims description 18
- 239000010452 phosphate Substances 0.000 claims description 17
- 229920000642 polymer Polymers 0.000 claims description 16
- 239000000835 fiber Substances 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 13
- 230000002378 acidificating effect Effects 0.000 claims description 11
- 239000011230 binding agent Substances 0.000 claims description 11
- 239000000499 gel Substances 0.000 claims description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 10
- 239000000314 lubricant Substances 0.000 claims description 8
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 8
- 102000008186 Collagen Human genes 0.000 claims description 7
- 108010035532 Collagen Proteins 0.000 claims description 7
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 claims description 7
- 229920001436 collagen Polymers 0.000 claims description 7
- 229920001577 copolymer Polymers 0.000 claims description 7
- 235000019821 dicalcium diphosphate Nutrition 0.000 claims description 7
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 7
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 7
- 229920002732 Polyanhydride Polymers 0.000 claims description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 210000002805 bone matrix Anatomy 0.000 claims description 6
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 6
- 229920000620 organic polymer Polymers 0.000 claims description 6
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 6
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 6
- 229920000049 Carbon (fiber) Polymers 0.000 claims description 5
- 239000004698 Polyethylene Substances 0.000 claims description 5
- 239000005313 bioactive glass Substances 0.000 claims description 5
- 239000004917 carbon fiber Substances 0.000 claims description 5
- 229920000573 polyethylene Polymers 0.000 claims description 5
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 5
- 239000004626 polylactic acid Substances 0.000 claims description 5
- 229920002307 Dextran Polymers 0.000 claims description 4
- 229920000954 Polyglycolide Polymers 0.000 claims description 4
- 229920000331 Polyhydroxybutyrate Polymers 0.000 claims description 4
- 229940043256 calcium pyrophosphate Drugs 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- 239000005015 poly(hydroxybutyrate) Substances 0.000 claims description 4
- 229920000728 polyester Polymers 0.000 claims description 4
- 239000004633 polyglycolic acid Substances 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 239000003104 tissue culture media Substances 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- 239000004952 Polyamide Substances 0.000 claims description 3
- 229920001710 Polyorthoester Polymers 0.000 claims description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 3
- ROPDWRCJTIRLTR-UHFFFAOYSA-L calcium metaphosphate Chemical compound [Ca+2].[O-]P(=O)=O.[O-]P(=O)=O ROPDWRCJTIRLTR-UHFFFAOYSA-L 0.000 claims description 3
- OLSDWRNWUGHKSY-UHFFFAOYSA-J dicalcium;phosphonato phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O OLSDWRNWUGHKSY-UHFFFAOYSA-J 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 229910000392 octacalcium phosphate Inorganic materials 0.000 claims description 3
- 229920005583 poly(anhydride-co-imide) Polymers 0.000 claims description 3
- 229920002647 polyamide Polymers 0.000 claims description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 3
- 229910052710 silicon Inorganic materials 0.000 claims description 3
- 239000010703 silicon Substances 0.000 claims description 3
- YIGWVOWKHUSYER-UHFFFAOYSA-F tetracalcium;hydrogen phosphate;diphosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].OP([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O YIGWVOWKHUSYER-UHFFFAOYSA-F 0.000 claims description 3
- 239000001993 wax Substances 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims 2
- 239000011521 glass Substances 0.000 claims 2
- 239000003921 oil Substances 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 abstract description 167
- 239000002243 precursor Substances 0.000 abstract description 152
- 239000002131 composite material Substances 0.000 abstract description 104
- 239000000376 reactant Substances 0.000 abstract description 30
- 230000008569 process Effects 0.000 abstract description 29
- 239000000945 filler Substances 0.000 abstract description 26
- 230000012010 growth Effects 0.000 abstract description 22
- 230000035876 healing Effects 0.000 abstract description 16
- 230000000399 orthopedic effect Effects 0.000 abstract description 16
- 208000010392 Bone Fractures Diseases 0.000 abstract description 13
- 239000004568 cement Substances 0.000 abstract description 13
- 230000001009 osteoporotic effect Effects 0.000 abstract description 12
- 210000001909 alveolar process Anatomy 0.000 abstract description 8
- 230000036760 body temperature Effects 0.000 abstract description 8
- 210000003781 tooth socket Anatomy 0.000 abstract description 8
- 230000001419 dependent effect Effects 0.000 abstract description 5
- 230000008467 tissue growth Effects 0.000 abstract 1
- 239000006072 paste Substances 0.000 description 118
- 239000008188 pellet Substances 0.000 description 59
- 210000004027 cell Anatomy 0.000 description 56
- 241001465754 Metazoa Species 0.000 description 54
- 210000001519 tissue Anatomy 0.000 description 48
- 239000000843 powder Substances 0.000 description 45
- 239000000523 sample Substances 0.000 description 45
- 239000007787 solid Substances 0.000 description 39
- 239000000243 solution Substances 0.000 description 35
- 238000002513 implantation Methods 0.000 description 34
- 238000004519 manufacturing process Methods 0.000 description 33
- 239000000126 substance Substances 0.000 description 33
- 230000011164 ossification Effects 0.000 description 29
- 238000001727 in vivo Methods 0.000 description 28
- 230000015572 biosynthetic process Effects 0.000 description 25
- 238000002360 preparation method Methods 0.000 description 25
- 230000009257 reactivity Effects 0.000 description 25
- 238000012360 testing method Methods 0.000 description 24
- 238000009826 distribution Methods 0.000 description 23
- 239000011159 matrix material Substances 0.000 description 22
- 230000001054 cortical effect Effects 0.000 description 21
- 238000002441 X-ray diffraction Methods 0.000 description 20
- 238000009472 formulation Methods 0.000 description 20
- 239000012153 distilled water Substances 0.000 description 19
- 238000000227 grinding Methods 0.000 description 19
- 238000001356 surgical procedure Methods 0.000 description 19
- 238000010438 heat treatment Methods 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 239000000316 bone substitute Substances 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 17
- 239000003112 inhibitor Substances 0.000 description 17
- 230000001737 promoting effect Effects 0.000 description 17
- 210000000515 tooth Anatomy 0.000 description 17
- 238000011282 treatment Methods 0.000 description 16
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 15
- 230000001965 increasing effect Effects 0.000 description 15
- 229910052500 inorganic mineral Inorganic materials 0.000 description 15
- 150000002500 ions Chemical class 0.000 description 15
- 235000010755 mineral Nutrition 0.000 description 15
- 239000011707 mineral Substances 0.000 description 15
- 230000008468 bone growth Effects 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 210000004872 soft tissue Anatomy 0.000 description 14
- 238000013459 approach Methods 0.000 description 13
- 239000002639 bone cement Substances 0.000 description 13
- 210000000845 cartilage Anatomy 0.000 description 13
- 238000010899 nucleation Methods 0.000 description 13
- 239000002244 precipitate Substances 0.000 description 13
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000002425 crystallisation Methods 0.000 description 12
- 230000008025 crystallization Effects 0.000 description 12
- 230000008439 repair process Effects 0.000 description 12
- 206010017076 Fracture Diseases 0.000 description 11
- 239000013078 crystal Substances 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 210000002303 tibia Anatomy 0.000 description 11
- 230000004927 fusion Effects 0.000 description 10
- 230000001976 improved effect Effects 0.000 description 10
- 238000001228 spectrum Methods 0.000 description 10
- 206010002091 Anaesthesia Diseases 0.000 description 9
- 241000282472 Canis lupus familiaris Species 0.000 description 9
- 230000037005 anaesthesia Effects 0.000 description 9
- 238000000576 coating method Methods 0.000 description 9
- 239000004053 dental implant Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 210000004373 mandible Anatomy 0.000 description 9
- 210000003205 muscle Anatomy 0.000 description 9
- 229920001432 poly(L-lactide) Polymers 0.000 description 9
- 238000001556 precipitation Methods 0.000 description 9
- GBNXLQPMFAUCOI-UHFFFAOYSA-H tetracalcium;oxygen(2-);diphosphate Chemical compound [O-2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GBNXLQPMFAUCOI-UHFFFAOYSA-H 0.000 description 9
- 206010016654 Fibrosis Diseases 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- 208000006735 Periostitis Diseases 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000004761 fibrosis Effects 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 210000003460 periosteum Anatomy 0.000 description 8
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 241000282465 Canis Species 0.000 description 7
- 239000000654 additive Substances 0.000 description 7
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 7
- 230000000975 bioactive effect Effects 0.000 description 7
- 230000000740 bleeding effect Effects 0.000 description 7
- 239000007795 chemical reaction product Substances 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 239000007758 minimum essential medium Substances 0.000 description 7
- 239000004570 mortar (masonry) Substances 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 239000012736 aqueous medium Substances 0.000 description 6
- 230000003416 augmentation Effects 0.000 description 6
- 210000001124 body fluid Anatomy 0.000 description 6
- 230000010478 bone regeneration Effects 0.000 description 6
- 239000000919 ceramic Substances 0.000 description 6
- 229910010293 ceramic material Inorganic materials 0.000 description 6
- 230000006835 compression Effects 0.000 description 6
- 238000007906 compression Methods 0.000 description 6
- 238000012377 drug delivery Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 6
- 230000036571 hydration Effects 0.000 description 6
- 238000006703 hydration reaction Methods 0.000 description 6
- 238000002329 infrared spectrum Methods 0.000 description 6
- 125000006850 spacer group Chemical group 0.000 description 6
- 230000001228 trophic effect Effects 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000000113 differential scanning calorimetry Methods 0.000 description 5
- 235000011180 diphosphates Nutrition 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 210000001624 hip Anatomy 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 239000010936 titanium Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 230000003444 anaesthetic effect Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 4
- 230000022159 cartilage development Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 210000001612 chondrocyte Anatomy 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000001627 detrimental effect Effects 0.000 description 4
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 238000002386 leaching Methods 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 238000010883 osseointegration Methods 0.000 description 4
- 230000004962 physiological condition Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000017423 tissue regeneration Effects 0.000 description 4
- 229910052719 titanium Inorganic materials 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 239000004134 Dicalcium diphosphate Substances 0.000 description 3
- 206010018691 Granuloma Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 229910004298 SiO 2 Inorganic materials 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 238000006065 biodegradation reaction Methods 0.000 description 3
- 229920013641 bioerodible polymer Polymers 0.000 description 3
- 210000002449 bone cell Anatomy 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 229910000393 dicalcium diphosphate Inorganic materials 0.000 description 3
- VLCINIKIVYNLPT-UHFFFAOYSA-J dicalcium;hydrogen phosphate Chemical compound [Ca+2].[Ca+2].OP(O)([O-])=O.[O-]P([O-])([O-])=O VLCINIKIVYNLPT-UHFFFAOYSA-J 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 3
- 229960001690 etomidate Drugs 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 208000010758 granulomatous inflammation Diseases 0.000 description 3
- 230000000887 hydrating effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 229910001425 magnesium ion Inorganic materials 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000006911 nucleation Effects 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 229940065514 poly(lactide) Drugs 0.000 description 3
- 229920002643 polyglutamic acid Polymers 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 239000011800 void material Substances 0.000 description 3
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 3
- IMLJLCJZQLGHJS-JEKSYDDFSA-N (4s,4ar,5s,5ar,6s,12ar)-4-(dimethylamino)-1,5,6,10,11,12a-hexahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;dihydrate Chemical compound O.O.C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O IMLJLCJZQLGHJS-JEKSYDDFSA-N 0.000 description 2
- LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 2
- ZHJGWYRLJUCMRT-UHFFFAOYSA-N 5-[6-[(4-methylpiperazin-1-yl)methyl]benzimidazol-1-yl]-3-[1-[2-(trifluoromethyl)phenyl]ethoxy]thiophene-2-carboxamide Chemical compound C=1C=CC=C(C(F)(F)F)C=1C(C)OC(=C(S1)C(N)=O)C=C1N(C1=C2)C=NC1=CC=C2CN1CCN(C)CC1 ZHJGWYRLJUCMRT-UHFFFAOYSA-N 0.000 description 2
- 206010066995 Alveolar osteitis Diseases 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 208000020084 Bone disease Diseases 0.000 description 2
- JUQPZRLQQYSMEQ-UHFFFAOYSA-N CI Basic red 9 Chemical compound [Cl-].C1=CC(N)=CC=C1C(C=1C=CC(N)=CC=1)=C1C=CC(=[NH2+])C=C1 JUQPZRLQQYSMEQ-UHFFFAOYSA-N 0.000 description 2
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 101710082751 Carboxypeptidase S1 homolog A Proteins 0.000 description 2
- 102100027992 Casein kinase II subunit beta Human genes 0.000 description 2
- 101710158100 Casein kinase II subunit beta Proteins 0.000 description 2
- 102100023804 Coagulation factor VII Human genes 0.000 description 2
- 229920004934 Dacron® Polymers 0.000 description 2
- 208000018035 Dental disease Diseases 0.000 description 2
- 208000001695 Dry Socket Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010015548 Euthanasia Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 240000002834 Paulownia tomentosa Species 0.000 description 2
- 235000010678 Paulownia tomentosa Nutrition 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 201000002820 alveolar periostitis Diseases 0.000 description 2
- 229910052586 apatite Inorganic materials 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229940125717 barbiturate Drugs 0.000 description 2
- QVQLCTNNEUAWMS-UHFFFAOYSA-N barium oxide Chemical compound [Ba]=O QVQLCTNNEUAWMS-UHFFFAOYSA-N 0.000 description 2
- 229940052223 basic fuchsin Drugs 0.000 description 2
- 210000004763 bicuspid Anatomy 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 238000007470 bone biopsy Methods 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000002316 cosmetic surgery Methods 0.000 description 2
- 239000002178 crystalline material Substances 0.000 description 2
- 210000003464 cuspid Anatomy 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 210000003298 dental enamel Anatomy 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000005530 etching Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000013038 hand mixing Methods 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- KBQIPTXDQGPPIO-UHFFFAOYSA-K heptacalcium;phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O KBQIPTXDQGPPIO-UHFFFAOYSA-K 0.000 description 2
- 238000000024 high-resolution transmission electron micrograph Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000010445 mica Substances 0.000 description 2
- 229910052618 mica group Inorganic materials 0.000 description 2
- 230000000921 morphogenic effect Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 210000004409 osteocyte Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- NPIJXCQZLFKBMV-YTGGZNJNSA-L pancuronium bromide Chemical compound [Br-].[Br-].C[N+]1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 NPIJXCQZLFKBMV-YTGGZNJNSA-L 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229940085991 phosphate ion Drugs 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 238000001020 plasma etching Methods 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000009101 premedication Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000036632 reaction speed Effects 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 239000012713 reactive precursor Substances 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000036387 respiratory rate Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000004576 sand Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 235000011008 sodium phosphates Nutrition 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000004381 surface treatment Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000000606 toothpaste Substances 0.000 description 2
- 229940034610 toothpaste Drugs 0.000 description 2
- 239000003204 tranquilizing agent Substances 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 230000036642 wellbeing Effects 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- OGQYJDHTHFAPRN-UHFFFAOYSA-N 2-fluoro-6-(trifluoromethyl)benzonitrile Chemical compound FC1=CC=CC(C(F)(F)F)=C1C#N OGQYJDHTHFAPRN-UHFFFAOYSA-N 0.000 description 1
- MGGVALXERJRIRO-UHFFFAOYSA-N 4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-2-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-1H-pyrazol-5-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)O MGGVALXERJRIRO-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229910004261 CaF 2 Inorganic materials 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 206010070245 Foreign body Diseases 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010020100 Hip fracture Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 241000757120 Mecolaesthus longissimus Species 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 208000023178 Musculoskeletal disease Diseases 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N Na2O Inorganic materials [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 201000007902 Primary cutaneous amyloidosis Diseases 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 208000004367 Tibial Fractures Diseases 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 238000002083 X-ray spectrum Methods 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000010669 acid-base reaction Methods 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 238000005275 alloying Methods 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229940064804 betadine Drugs 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 239000005312 bioglass Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- GEHJBWKLJVFKPS-UHFFFAOYSA-N bromochloroacetic acid Chemical compound OC(=O)C(Cl)Br GEHJBWKLJVFKPS-UHFFFAOYSA-N 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- ZBZJARSYCHAEND-UHFFFAOYSA-L calcium;dihydrogen phosphate;hydrate Chemical compound O.[Ca+2].OP(O)([O-])=O.OP(O)([O-])=O ZBZJARSYCHAEND-UHFFFAOYSA-L 0.000 description 1
- KMQAPZBMEMMKSS-UHFFFAOYSA-K calcium;magnesium;phosphate Chemical compound [Mg+2].[Ca+2].[O-]P([O-])([O-])=O KMQAPZBMEMMKSS-UHFFFAOYSA-K 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960003185 chlortetracycline hydrochloride Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000003479 dental cement Substances 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 229910000388 diammonium phosphate Inorganic materials 0.000 description 1
- 235000019838 diammonium phosphate Nutrition 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000002019 doping agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000005489 elastic deformation Effects 0.000 description 1
- 238000004453 electron probe microanalysis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 210000002436 femur neck Anatomy 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- 229960004207 fentanyl citrate Drugs 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 238000009730 filament winding Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 210000001214 frontal sinus Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000007542 hardness measurement Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 210000001981 hip bone Anatomy 0.000 description 1
- 238000011540 hip replacement Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000002083 iodinating effect Effects 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000001847 jaw Anatomy 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 238000010030 laminating Methods 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 210000005009 osteogenic cell Anatomy 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229960003379 pancuronium bromide Drugs 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 208000014670 posterior cortical atrophy Diseases 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 238000000513 principal component analysis Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 239000012783 reinforcing fiber Substances 0.000 description 1
- 239000012779 reinforcing material Substances 0.000 description 1
- 230000000395 remineralizing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229940069575 rompun Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 239000003356 suture material Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000002076 thermal analysis method Methods 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 230000014599 transmission of virus Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/02—Surgical adhesives or cements; Adhesives for colostomy devices containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/12—Phosphorus-containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/42—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix
- A61L27/425—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix of phosphorus containing material, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00179—Ceramics or ceramic-like structures
- A61F2310/00293—Ceramics or ceramic-like structures containing a phosphorus-containing compound, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Composite Materials (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Materials Engineering (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/729,344 US6117456A (en) | 1995-05-19 | 1996-10-16 | Methods and products related to the physical conversion of reactive amorphous calcium phosphate |
| US08/729343 | 1996-10-16 | ||
| US08/729,343 US20020136696A1 (en) | 1995-05-19 | 1996-10-16 | Orthopedic and dental ceramic implants |
| US08/732016 | 1996-10-16 | ||
| US08/732,016 US6027742A (en) | 1995-05-19 | 1996-10-16 | Bioresorbable ceramic composites |
| US08/729344 | 1996-10-16 | ||
| PCT/US1997/018631 WO1998016268A2 (en) | 1996-10-16 | 1997-10-16 | Method of preparing a poorly crystalline calcium phosphate and methods of its use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU4674697A AU4674697A (en) | 1998-05-11 |
| AU742748B2 true AU742748B2 (en) | 2002-01-10 |
Family
ID=27419129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU46746/97A Ceased AU742748B2 (en) | 1996-10-16 | 1997-10-16 | Method of preparing a poorly crystalline calcium phosphate and methods of its use |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0936929B1 (enExample) |
| JP (1) | JP4781494B2 (enExample) |
| AT (1) | ATE269720T1 (enExample) |
| AU (1) | AU742748B2 (enExample) |
| CA (1) | CA2270185C (enExample) |
| DE (1) | DE69729647T2 (enExample) |
| DK (1) | DK0936929T3 (enExample) |
| ES (1) | ES2227719T3 (enExample) |
| WO (1) | WO1998016268A2 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6554803B1 (en) | 1997-04-02 | 2003-04-29 | Arthur Ashman | Combination syringe and aspirator for bone regeneration material and method for using the syringe |
| IT1299563B1 (it) * | 1998-07-17 | 2000-03-16 | Giovanni Dolci | Uso odontostomatologico di materiali a base apatitica nanostrutturati |
| WO2000015273A1 (de) | 1998-09-11 | 2000-03-23 | Gerhard Schmidmaier | Biologisch aktive implantate |
| ATE291386T1 (de) * | 1999-10-21 | 2005-04-15 | Arthur Ashman | Kombination von spritze und sauger für knochenregenerationsmaterial |
| JP4669932B2 (ja) * | 2000-05-02 | 2011-04-13 | 学校法人日本大学 | 生体材料用組成物及びその硬化体 |
| JP4726281B2 (ja) * | 2000-07-27 | 2011-07-20 | テルモ株式会社 | 体内注入可能な組成物 |
| AU2006902A (en) * | 2000-10-24 | 2002-05-06 | Sdgi Holdings Inc | Methods and instruments for treating pseudoarthrosis |
| ES2319506T3 (es) * | 2000-10-24 | 2009-05-08 | Warsaw Orthopedic, Inc. | Metodos y dispositivos de fusion vertebral. |
| JP2002226241A (ja) * | 2001-01-30 | 2002-08-14 | Mitsui Constr Co Ltd | 真空凍結乾燥によるコンクリート材料のリサイクル方法 |
| JP2002296205A (ja) * | 2001-03-29 | 2002-10-09 | Japan Tissue Engineering:Kk | 培養組織の元素組成分析方法、移植適性判定方法及び品質管理方法並びに、移植適性を有する培養組織の製造方法及び移植適性を有する培養組織 |
| US6730324B2 (en) | 2001-04-20 | 2004-05-04 | The University Of British Columbia | Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation |
| DK1448246T4 (en) | 2001-11-19 | 2015-12-21 | Scil Technology Gmbh | Homogeneously coated device with osteoinductive and osteoconductive properties |
| US6840961B2 (en) * | 2001-12-21 | 2005-01-11 | Etex Corporation | Machinable preformed calcium phosphate bone substitute material implants |
| PL207552B1 (pl) | 2002-09-10 | 2010-12-31 | Scil Technology Gmbh | Sposób wytwarzania urządzenia, urządzenie, kompozycja farmaceutyczna, zastosowanie urządzenia i zestaw |
| US7776594B2 (en) | 2002-10-10 | 2010-08-17 | Wright Medical Technology, Inc. | Bone marrow infusion chamber and method |
| FR2850282B1 (fr) | 2003-01-27 | 2007-04-06 | Jerome Asius | Implant injectable a base de ceramique pour le comblement de rides, depressions cutanees et cicatrices, et sa preparation |
| GB0307011D0 (en) | 2003-03-27 | 2003-04-30 | Regentec Ltd | Porous matrix |
| WO2005046440A2 (en) | 2003-11-07 | 2005-05-26 | Calcitec, Inc. | Spinal fusion procedure using an injectable bone substitute |
| DE10357460A1 (de) * | 2003-12-04 | 2005-07-07 | Friedrich-Baur-Gmbh | Bioresorbierbares Material |
| US20050136764A1 (en) | 2003-12-18 | 2005-06-23 | Sherman Michael C. | Designed composite degradation for spinal implants |
| US7459018B2 (en) | 2005-04-08 | 2008-12-02 | Howmedica Leibinger Inc. | Injectable calcium phosphate cement |
| US7416602B2 (en) | 2005-04-08 | 2008-08-26 | Howmedica Leibinger, Inc. | Calcium phosphate cement |
| DE102005022176B4 (de) * | 2005-05-09 | 2009-06-25 | Martin-Luther-Universität Halle-Wittenberg | Verfahren zur Herstellung von bioresorbierbaren Verbundmaterialien und seine Verwendung als Implantatmaterial sowie bioresorbiebaren Verbundmaterialien |
| DE102007048591A1 (de) * | 2007-10-05 | 2009-04-09 | Matthias Prof. Dr. Epple | Implantat und Verfahren zu seiner Herstellung |
| ES2428263T3 (es) * | 2008-01-09 | 2013-11-06 | Oswestry Tissue Bank Ltd. | Método para fabricar una composición para la reparación ósea |
| JP6324653B2 (ja) * | 2008-04-15 | 2018-05-16 | ライフ サイエンス エンタープライジズ インコーポレイテッド | リン酸カルシウム配合骨セメントを用いる脊椎骨の最小侵襲治療（ｍｉｔｖ） |
| AU2015215892B2 (en) * | 2008-04-15 | 2017-11-30 | Life Science Enterprises, Inc. | Minimally invasive treatment of vertebra (mitv) using a calcium phosphate combination bone cement |
| US8709149B2 (en) | 2008-11-12 | 2014-04-29 | Ossdsign Ab | Hydraulic cements, methods and products |
| WO2011058443A1 (en) * | 2009-11-13 | 2011-05-19 | Barralet Jake E | Method and device to induce collagen biomineralisation |
| KR101901821B1 (ko) | 2010-03-10 | 2018-09-27 | 오에스에스-큐 에이비 | 임플란트 및 조직 결함의 교정 방법 |
| EP2637983B1 (en) | 2010-11-10 | 2018-12-26 | Stryker European Holdings I, LLC | Process for the preparation of a polymeric bone foam |
| US9463046B2 (en) | 2011-08-22 | 2016-10-11 | Ossdsign Ab | Implants and methods for using such implants to fill holes in bone tissue |
| US8591645B2 (en) | 2011-09-09 | 2013-11-26 | Ossdsign Ab | Hydraulic cements with optimized grain size distribution, methods, articles and kits |
| US20130066327A1 (en) | 2011-09-09 | 2013-03-14 | Håkan Engqvist | Hydraulic cement compositions with low ph methods, articles and kits |
| DE102012108320A1 (de) * | 2012-09-07 | 2014-03-13 | Aap Biomaterials Gmbh | Knochenzement sowie unter Verwendung eines Knochenzements hergestellter Formkörper |
| CN104853783B (zh) | 2012-12-14 | 2018-03-02 | 奥斯设计公司 | 形成水泥的组合物、三斜磷钙石水泥、植入物及用于矫正骨缺损的方法 |
| WO2014125381A2 (en) | 2013-02-12 | 2014-08-21 | Ossdsign Ab | Mosaic implants, kits and methods for correcting bone defects |
| US10881519B2 (en) | 2014-08-14 | 2021-01-05 | Ossdsign Ab | Bone implants for correcting bone defects |
| KR101631387B1 (ko) * | 2014-11-27 | 2016-06-16 | 에스케이이노베이션 주식회사 | 2,3-부탄디올로부터 1,3-부타디엔 및 메틸에틸케톤을 제조하는 데 사용되는 무정형 칼슘 포스페이트 촉매 및 촉매 제조 방법 |
| JP2016209599A (ja) * | 2016-05-20 | 2016-12-15 | ライフ サイエンス エンタープライジズ インコーポレイテッド | リン酸カルシウム配合骨セメントを用いる脊椎骨の最小侵襲治療（ｍｉｔｖ） |
| CN109663147B (zh) * | 2019-02-19 | 2022-07-05 | 邢叔星 | 一种附着磷酸三钙缓释抗生素的peek植骨体及其制备方法 |
| CN118806988B (zh) * | 2023-04-21 | 2025-09-23 | 浙江大学 | 一种仿生多级球状矿化胶原支架的制备方法及应用 |
| CN116836022B (zh) * | 2023-06-25 | 2025-09-12 | 中国地质大学（武汉） | 一种多功能矿物土壤调理剂及其制备方法 |
| CN117383529A (zh) * | 2023-09-12 | 2024-01-12 | 华南理工大学 | 一种降低无定形磷酸钙稳定性的方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995008319A1 (en) * | 1993-09-24 | 1995-03-30 | American Dental Association Health Foundation | Self-setting calcium phosphate cements and methods for preparing and using them |
| AU5865996A (en) * | 1995-05-19 | 1996-11-29 | Etex Corporation | Bone substitution material and a method of its manufacture |
| AU7723596A (en) * | 1995-11-07 | 1997-05-29 | Etex Corporation | Low temperature calcium phosphate apatite and a method of its manufacture |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6117409A (ja) * | 1984-07-02 | 1986-01-25 | Meishin Toryo Kk | 非晶質リン酸カルシウムの製法およびこれを主成分とする生体適応性組成物 |
| JPS62224356A (ja) * | 1986-03-26 | 1987-10-02 | 太平化学産業株式会社 | 生体硬組織補修材料およびその製造法 |
| JPH01166765A (ja) * | 1987-12-23 | 1989-06-30 | Kobe Steel Ltd | 代替骨およびその製造方法 |
| US4880610A (en) * | 1988-04-20 | 1989-11-14 | Norian Corporation | In situ calcium phosphate minerals--method and composition |
| US5037639A (en) * | 1989-05-24 | 1991-08-06 | American Dental Association Health Foundation | Methods and compositions for mineralizing calcified tissues |
| CA2088169C (en) * | 1990-07-27 | 2002-04-23 | Brent R. Constantz | Intimate mixture of calcium and phosphate sources as precursor to hydroxyapatite |
| JP3115642B2 (ja) * | 1991-06-07 | 2000-12-11 | 日揮株式会社 | 人工骨材 |
| DE69205736T2 (de) * | 1991-06-26 | 1996-06-13 | Nitta Gelatin Kk | Härtbares kalziumphosphathaltiges Material zum Reparieren von lebenden Hartgeweben. |
| GB9215356D0 (en) * | 1992-07-20 | 1992-09-02 | Univ Reading The | Bone materials |
| EP0672117A4 (en) * | 1992-08-13 | 1996-06-12 | Univ Pennsylvania | MATRIX BASED ON A BIOACTIVE MATERIAL FOR THE SYNTHESIS -i (IN VITRO) OF BONE TISSUE. |
-
1997
- 1997-10-16 AU AU46746/97A patent/AU742748B2/en not_active Ceased
- 1997-10-16 DE DE69729647T patent/DE69729647T2/de not_active Expired - Lifetime
- 1997-10-16 ES ES97945578T patent/ES2227719T3/es not_active Expired - Lifetime
- 1997-10-16 AT AT97945578T patent/ATE269720T1/de not_active IP Right Cessation
- 1997-10-16 EP EP97945578A patent/EP0936929B1/en not_active Expired - Lifetime
- 1997-10-16 JP JP51857598A patent/JP4781494B2/ja not_active Expired - Lifetime
- 1997-10-16 WO PCT/US1997/018631 patent/WO1998016268A2/en not_active Ceased
- 1997-10-16 DK DK97945578T patent/DK0936929T3/da active
- 1997-10-16 CA CA002270185A patent/CA2270185C/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995008319A1 (en) * | 1993-09-24 | 1995-03-30 | American Dental Association Health Foundation | Self-setting calcium phosphate cements and methods for preparing and using them |
| AU5865996A (en) * | 1995-05-19 | 1996-11-29 | Etex Corporation | Bone substitution material and a method of its manufacture |
| AU7723596A (en) * | 1995-11-07 | 1997-05-29 | Etex Corporation | Low temperature calcium phosphate apatite and a method of its manufacture |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0936929B1 (en) | 2004-06-23 |
| DE69729647D1 (de) | 2004-07-29 |
| CA2270185A1 (en) | 1998-04-23 |
| DK0936929T3 (da) | 2004-11-08 |
| CA2270185C (en) | 2009-01-06 |
| AU4674697A (en) | 1998-05-11 |
| WO1998016268A2 (en) | 1998-04-23 |
| ATE269720T1 (de) | 2004-07-15 |
| EP0936929A2 (en) | 1999-08-25 |
| ES2227719T3 (es) | 2005-04-01 |
| JP4781494B2 (ja) | 2011-09-28 |
| JP2001502215A (ja) | 2001-02-20 |
| DE69729647T2 (de) | 2005-07-07 |
| WO1998016268A3 (en) | 1998-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU742748B2 (en) | Method of preparing a poorly crystalline calcium phosphate and methods of its use | |
| US6953594B2 (en) | Method of preparing a poorly crystalline calcium phosphate and methods of its use | |
| US7517539B1 (en) | Method of preparing a poorly crystalline calcium phosphate and methods of its use | |
| US6287341B1 (en) | Orthopedic and dental ceramic implants | |
| US6117456A (en) | Methods and products related to the physical conversion of reactive amorphous calcium phosphate | |
| US6331312B1 (en) | Bioresorbable ceramic composites | |
| JP4260880B2 (ja) | 骨代用物質及びその製造方法 | |
| EP0941079B1 (en) | Bioceramic compositions | |
| US6201039B1 (en) | Bone substitute composition comprising hydroxyapatite and a method of production therefor | |
| US7150879B1 (en) | Neutral self-setting calcium phosphate paste | |
| US6132463A (en) | Cell seeding of ceramic compositions | |
| JP5091188B2 (ja) | 骨誘導性タンパク質のためのリン酸カルシウム送達ビヒクル | |
| US20030055512A1 (en) | Calcium based neutral and bioresorbable bone graft | |
| KR101420100B1 (ko) | 다목적 생체재료 조성물 | |
| US20020136696A1 (en) | Orthopedic and dental ceramic implants | |
| Weiss et al. | Calcium phosphate bone cements: a comprehensive review | |
| WO2006076426A2 (en) | Multi-purpose bio-material composition | |
| JP2003335574A (ja) | 貫通孔を有する球状リン酸カルシウム系セラミックス及びその用途 | |
| Atiyah et al. | STUDY THE EFFECT OF AVIAN EGGSHELL HYDROXYAPATITE POWDER ON BONE GAPS HEALING IN RABBITS. | |
| WO2007046109A2 (en) | System and method for bone repair and/or bone augmentation | |
| Lv et al. | Calcium‐Phosphate‐Based Ceramics for Biomedical Applications | |
| Gonçalves | Substitutos Ósseos injectáveis prontos a usar | |
| Passuti et al. | Bone substitutes | |
| Jansen | Kemal Sarıibrahimoğlu, Sander CG Leeuwenburgh, Joop GC Wolke | |
| MXPA97008849A (es) | Material substituto oseo y metodo para su preparacion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |